BioCryst Pharmaceuticals, Inc.（BCRX）資訊與事件BCRXBioCryst Pharmaceuticals, Inc.

BioCryst Receives Japan Approval for Orladeyo in Pediatric Patients

BioCryst announced that Japan's Ministry of Health, Labor and Welfare has granted marketing approval for once-daily Orladeyo for prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to less than 12 years.

BioCryst Appoints David Jenkins as Chief Scientific Officer

BioCryst (BCRX) announced the appointment of David Jenkins to the newly created position of chief scientific officer, effective immediately, reporting to Sandeep Menon, chief research and development Officer. In this role, Jenkins will build and lead a research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of rare disease therapies to patients. He will be based in the company's Boston office. He most recently served as senior VP, head of research and external innovation at Ipsen (IPSEY).

Wedbush: Vertex Acquires Crinetics for $85/Share

Wedbush notes that Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85/share in cash. Crinetics now trades essentially at the deal price, reflecting high confidence in closing. For Vertex, the firm views this as a sound, if modestly dilutive near-term, strategic deal. Wedbush would expect Vertex's underperformance to be temporary as the deal reinforces the durability of its M&A-driven pipeline diversification strategy following recent moves in kidney disease and other rare-disease areas. The firm tells investors to watch other commercial-stage rare/endocrine-disease names such as BioCryst Pharmaceuticals (BCRX) and Ascendis Pharma (ASND) as potential next targets, given the rich premium paid here.